Skip to main content
Armata Pharmaceuticals, Inc. logo

Armata Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ARMP ISIN · US04216R1023 LEI · 549300QM1VCWH8KT0S21 US Manufacturing
Open in API
Filings indexed 1,011 across all filing types
Latest filing 2008-05-12 Earnings Release
Country US United States of America
Listing US ARMP

About Armata Pharmaceuticals, Inc.

https://www.armatapharma.com/

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat the global threat of antibiotic-resistant infections. The company's core focus is on creating precisely targeted, high-purity phage-based treatments for serious bacterial infections. This approach aims to provide an effective alternative to conventional antibiotics by eliminating harmful bacteria while preserving the patient's healthy microbiome. Armata's pipeline includes product candidates targeting multi-drug resistant pathogens, supported by its in-house cGMP manufacturing facility for clinical and commercial supply.

Recent filings

Filing Released Lang Actions
Earnings Release 2008
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions "Item 2.02. Results of Operations and Financial Condition" and states that the company announced financial results for the quarter ended March 31, 2008. It also references a press release attached as Exhibit 99.1. The document itself is short (2420 characters) and primarily serves as a vehicle to announce the earnings release rather than containing detailed financial statements or analysis. According to the rules, initial announcements of quarterly financial results in a press release format correspond to an Earnings Release (ER). The 8-K is used here to file the earnings release. Therefore, the correct classification is Earnings Release (ER).
2008-05-12 English
BIOGEN IDEC, INC.
Major Shareholding Notification
2008-05-08 English
Interim / Quarterly Report 2008
Interim / Quarterly Report Q1 2008
2008-05-07 English
PRIMARY DOCUMENT
Director's Dealing
2008-04-30 English
Delisting Announcement 2008
Delisting Announcement Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated April 23, 2008, by Targeted Genetics Corporation. The content focuses on a notice of delisting due to the company's stock price falling below the minimum bid price requirement for continued listing on Nasdaq. It details the deficiency letter received, the compliance period allowed, and the potential for appeal. There are no financial statements or detailed financial data presented, nor is this an announcement of earnings or management changes. The primary subject is the delisting notice and related compliance information. According to the filing definitions, this matches the category of a Delisting Announcement (DLST). The document length is 3432 characters, which is sufficient to contain substantive information about the delisting event rather than just a brief announcement or a report publication notice. Therefore, the correct classification is DLST with high confidence.
2008-04-25 English
PRIMARY DOCUMENT
Director's Dealing
2008-04-15 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.